News

Study findings could help researchers better tailor their drug-delivery particles to specific types of cancer, or design new particles that take advantage of the biological features of particular types of cancer cells.

A new link discovered between the Parkinson's disease-associated protein alpha-synuclein and inflammation could provide a target for new treatments.

Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, describe a different way to build a COVID-19 vaccine, one that would, in theory, remain effective against new and emerging variants and could be taken as a pill, by inhalation or other delivery methods.

A research team has developed an inexpensive and simple-to-manufacture alternative to microplastic-based encapsulations, using silk. The novel process is published in the journal Small.

Researchers have used a novel strategy to study host cell proteins that contribute to the multiplication of the Lassa virus, which causes a severe hemorrhagic fever disease. This could lead to potential new drug targets for treating the disease.

Researchers have developed a promising new non-opioid painkiller, potentially with fewer side effects compared to other potent painkillers, and a unique mode of action, potentially opening a new pipeline for the development of analgesic drugs.

Charged nanoparticles could be used to deliver cancer vaccines directly to the tumor, enabling a localized immune response against the tumor.

Researchers found that antibiotics have sex-specific effects on the gut microbiome makeup of male and female laboratory rats, which could have implications for use in humans.

A University of Minnesota Twin Cities team has, for the first time, developed a new tool to predict and customize the rate of a specific kind of DNA editing called “site-specific recombination.” The research paves the way for more personalized, efficient genetic and cell therapies for diseases such as diabetes and cancer.

Testing vaccines in the field is challenging and requires large number of volunteers and long periods of follow-up. Now, scientists report a new way to test vaccines that may be as rigorous and stringent as exposure to field strains of malaria.